Shattuck Labs Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Shattuck LabsDer Gewinn des Unternehmens wird voraussichtlich um 16.5% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 63.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 2.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -63% betragen.

Wichtige Informationen

-16.5%

Wachstumsrate der Gewinne

-2.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	63.8%
Zukünftige Eigenkapitalrendite	-63.0%
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 18

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Feb 25

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Nov 23

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Aug 24

Shattuck Labs names Abhinav Shukla as chief technical officer

Jun 01

Shattuck Labs EPS beats by $0.11, beats on revenue

May 10

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

May 07

Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?

Mar 08

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely

Jan 12

Shattuck Labs reports Q3 results

Nov 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:STTK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2	-164	-105	N/A	3
12/31/2025	1	-97	-72	N/A	4
12/31/2024	2	-83	-74	N/A	5
3/31/2024	3	-85	-71	-71	N/A
12/31/2023	2	-87	-82	-81	N/A
9/30/2023	1	-95	-87	-86	N/A
6/30/2023	1	-92	-99	-97	N/A
3/31/2023	1	-98	-104	-95	N/A
12/31/2022	1	-102	-106	-94	N/A
9/30/2022	30	-69	-102	-89	N/A
6/30/2022	32	-61	-87	-74	N/A
3/31/2022	28	-58	-80	-72	N/A
12/31/2021	30	-45	-65	-57	N/A
9/30/2021	1	-65	-59	-52	N/A
6/30/2021	2	-59	-56	-51	N/A
3/31/2021	9	-42	-38	-34	N/A
12/31/2020	10	-37	-34	-34	N/A
9/30/2020	11	-32	-28	-27	N/A
6/30/2020	11	-27	-24	-23	N/A
3/31/2020	10	-26	-29	-28	N/A
12/31/2019	10	-24	-21	-21	N/A
12/31/2018	22	-7	-8	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: STTK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: STTK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: STTK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: STTKDie Einnahmen des Unternehmens (63.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: STTKDie Einnahmen des Unternehmens (63.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: STTK wird voraussichtlich in 3 Jahren unrentabel sein.

Shattuck Labs Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.9% to US$14.50

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

Consensus revenue estimates increase by 170%

Price target increased by 21% to US$15.50

Consensus revenue estimates increase by 78%, EPS downgraded

Recent updates

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Price target decreased by 7.9% to US$14.50

Shattuck Labs, Inc. Announces Committee Appointments

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)

High number of new and inexperienced directors

General Counsel notifies of intention to sell stock

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$2.31m

General Counsel notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Shattuck Labs names Abhinav Shukla as chief technical officer

Co-Founder & Chairman of the Board notifies of intention to sell stock

Co-Founder & Chairman of the Board notifies of intention to sell stock